The Week in Review: Tasly Pharma to Build US Manufacturing Facility

Tianjin Tasly Pharma will invest $40 million into a US facility to support its TCM-based treatment for coronary disease; Livzon Pharma will spend $154 million to build two new API fabrication facilities; Pfizer and Zhejiang Hisun Pharma signed an MOU to form a branded generics JV; Zhejiang Huahai Pharma received FDA approval of a generic Alzheimer’s treatment, donepezil; KingMed Diagnostics, a China diagnostic laboratory, will get second-opinion pathology consultations from the University of Pennsylvania Medical Center; First China Pharma has begun due diligence on its acquisition of a South China drug distributor; D-Pharm out-licensed China rights for its epilepsy treatment to Jiangsu Nhwa Pharma; and all eleven defendants charged with selling counterfeit Avastin have pled guilty. More details…. Stock Symbols: (SHA: 600535) (SHE: 200513) (NYSE: PFE) (SHA: 600267) (SHE: 600521) (OTCBB: FCPG) (TASE: DPRM) (SHE: 2262) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});